{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:52:56Z","timestamp":1784141576546,"version":"3.55.0"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018987","name":"Ministerul Cercet\u0103rii, Inov\u0103rii \u015fi Digitaliz\u0103rii","doi-asserted-by":"publisher","award":["23020101"],"award-info":[{"award-number":["23020101"]}],"id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007336","name":"University of Bucharest","doi-asserted-by":"publisher","award":["CNFIS-FDI-2025-F-0364"],"award-info":[{"award-number":["CNFIS-FDI-2025-F-0364"]}],"id":[{"id":"10.13039\/501100007336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.colsurfb.2025.114829","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:51:18Z","timestamp":1748519478000},"page":"114829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Nanotechnology-driven enhancement and modulation of immune responses in monkeypox and respiratory syncytial virus nanovaccine research"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8968-504X","authenticated-orcid":false,"given":"Adelina-Gabriela","family":"Niculescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei-Mihai","family":"Dumitrascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-1711","authenticated-orcid":false,"given":"An\u0131l Tevfik","family":"Ko\u00e7er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin Pelit","family":"Aray\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-2453","authenticated-orcid":false,"given":"Selcen Ar\u0131","family":"Yuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0517-7422","authenticated-orcid":false,"given":"Sinem","family":"Ko\u00e7er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem B\u00fclent","family":"\u00dcst\u00fcnda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru Mihai","family":"Grumezescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneliu Ovidiu","family":"Vrancianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara Madalina","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Paun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Carmen","family":"Chifiriuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2025.114829_bib1","article-title":"Monkeypox outbreaks in the context of the COVID-19 pandemic: Network and clustering analyses of global risks and modified SEIR prediction of epidemic trends","volume":"11","author":"Gao","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.colsurfb.2025.114829_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102089","article-title":"Why has the epidemiology of RSV changed during the COVID-19 pandemic?","volume":"61","author":"Abu-Raya","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.colsurfb.2025.114829_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jiph.2023.02.003","article-title":"Monkeypox (mpox) virus: classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis","volume":"16","author":"Karagoz","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.colsurfb.2025.114829_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rineng.2024.102985","article-title":"Early detection of monkeypox: Analysis and optimization of pretrained deep learning models using the Sparrow Search Algorithm","volume":"24","author":"Bamaqa","year":"2024","journal-title":"Results Eng."},{"key":"10.1016\/j.colsurfb.2025.114829_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bspc.2024.107125","article-title":"Optimized Global Aware Siamese Network based Monkeypox disease classification using skin images","volume":"101","author":"Muthulakshmi","year":"2025","journal-title":"Biomed. Signal Process. Control"},{"key":"10.1016\/j.colsurfb.2025.114829_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2024.102593","article-title":"Monkeypox Global Research: A Comprehensive Analysis from Emergence to Present (1961\u20132023) for innovative prevention and control approaches","volume":"18","author":"Kameli","year":"2025","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.colsurfb.2025.114829_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/vaccines11020428","article-title":"Nanomedicine as a Potential Tool against Monkeypox","volume":"11","author":"Mohamed","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.colsurfb.2025.114829_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1823","article-title":"Antiviral nanopharmaceuticals: Engineered surface interactions and virus-selective activity","volume":"14","author":"Kolanthai","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.nanoso.2024.101109","article-title":"Trends in nanomaterial types, synthesis methods, properties and uses: Toxicity, environmental concerns and economic viability","volume":"37","author":"Saleh","year":"2024","journal-title":"Nano-Struct. Nano-Objects"},{"key":"10.1016\/j.colsurfb.2025.114829_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmii.2023.12.006","article-title":"Monkeypox: An outbreak of a rare viral disease","volume":"57","author":"Luo","year":"2024","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.colsurfb.2025.114829_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41564-024-01690-1","article-title":"Understanding the biology of monkeypox virus to prevent future outbreaks","volume":"9","author":"Moss","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220415120","article-title":"Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model","volume":"120","author":"Americo","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.colsurfb.2025.114829_bib13","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1099\/vir.0.81215-0","article-title":"A tale of two clades: monkeypox viruses","volume":"86","author":"Likos","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib14","article-title":"Monkeypox clade IIb in France in 2023\u20132024","volume":"47","author":"Rahi","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.colsurfb.2025.114829_bib15","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0140-6736(24)02188-3","article-title":"Genetic sequencing analysis of monkeypox virus clade I in Republic of the Congo: a cross-sectional, descriptive study","volume":"404","author":"Yinda","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.colsurfb.2025.114829_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101971","article-title":"Tailoring multivalent nanomedicines for monkeypox","volume":"52","author":"Ovais","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.colsurfb.2025.114829_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102855","article-title":"The 2022 outbreak and the pathobiology of the monkeypox virus","volume":"131","author":"Kumar","year":"2022","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.colsurfb.2025.114829_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/v15010040","article-title":"A Customized Monkeypox Virus Genomic Database (MPXV DB v1.0) for Rapid Sequence Analysis and Phylogenomic Discoveries in CLC Microbial Genomics","volume":"15","author":"Shen-Gunther","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib19","first-page":"1","article-title":"Monkeypox virus: a comprehensive review of taxonomy, evolution, epidemiology, diagnosis, prevention, and control regiments so far","volume":"2","author":"Parvin","year":"2022","journal-title":"Ger. J. Microbiol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.10.002","article-title":"The evolving epidemiology of monkeypox virus","volume":"68","author":"Li","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.colsurfb.2025.114829_bib21","doi-asserted-by":"crossref","first-page":"e0003850","DOI":"10.1371\/journal.pntd.0003850","article-title":"BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-\/-) Mice from Monkeypoxvirus Lethal Challenge","volume":"9","author":"Franceschi","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.colsurfb.2025.114829_bib22","doi-asserted-by":"crossref","unstructured":"M.M. Christodoulidou, N.A. Mabbott2023. Efficacy of smallpox vaccines against Mpox infections in humans. Immunother. Adv. 3, ltad020. https:\/\/doi.org\/10.1093\/immadv\/ltad020..","DOI":"10.1093\/immadv\/ltad020"},{"key":"10.1016\/j.colsurfb.2025.114829_bib23","article-title":"A bioinformatics approach to systematically analyze the molecular patterns of monkeypox virus-host cell interactions","volume":"10","author":"Tang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.colsurfb.2025.114829_bib24","unstructured":"World Health Organization, Mpox outbreak, https:\/\/www.who.int\/emergencies\/situations\/mpox-outbreak (2024)(accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib25","first-page":"369","article-title":"Antiviral treatment against monkeypox: a scoping review","volume":"7","author":"Ortiz-Saavedra","year":"2022","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.colsurfb.2025.114829_bib26","first-page":"1969","article-title":"Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review","volume":"13","author":"Bruno","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib27","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00210-023-02769-y","article-title":"Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements","volume":"397","author":"Rani","year":"2024","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1164","article-title":"Clinical considerations on monkeypox antiviral medications: An overview","volume":"12","author":"Pourkarim","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.colsurfb.2025.114829_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/biomedicines11020278","article-title":"Oral brincidofovir therapy for monkeypox outbreak: a focused review on the therapeutic potential, clinical studies, patent literature, and prospects","volume":"11","author":"Imran","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.colsurfb.2025.114829_bib30","unstructured":"2024National Institute of Allergy and Infectious Diseases, Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine, (accessed 28 November 2024)https:\/\/clinicaltrials.gov\/study\/NCT05512949."},{"key":"10.1016\/j.colsurfb.2025.114829_bib31","unstructured":"Public Health England, Cohort Study of Healthcare Workers Receiving Imvanex\u00ae, https:\/\/clinicaltrials.gov\/study\/NCT03745131 (2020) (accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib32","unstructured":"McMaster University, Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: a Cluster RCT (SMART), https:\/\/clinicaltrials.gov\/study\/NCT05745987 (2024) (accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib33","unstructured":"Universidad Nacional de Colombia, Efficacy\/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia (MPOX-COL), https:\/\/clinicaltrials.gov\/study\/NCT06223919 (2024) (accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib34","unstructured":"Fundaci\u00f3n FLS de Lucha Contra el Sida las EI y la P de la S y la C, Break-through Infection Following Mpox Vaccination (REMAIN), https:\/\/clinicaltrials.gov\/study\/NCT05522296 (2024) (accessed 3 February 2025).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib35","unstructured":"Institute of Tropical Medicine, Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk (POQS-FU PLUS), https:\/\/clinicaltrials.gov\/study\/NCT05879965 (2023)(accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib36","unstructured":"2023, Assistance PubliqueH\u00f4pitaux de Paris, Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study (MonkeyVax) (accessed 3 February 2025)https:\/\/clinicaltrials.gov\/study\/NCT05438953."},{"key":"10.1016\/j.colsurfb.2025.114829_bib37","unstructured":"Bavarian Nordic, Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections, https:\/\/clinicaltrials.gov\/study\/NCT06549530 (2024)(accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib38","unstructured":"National Institute of Allergy and Infectious Diseases, Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC, https:\/\/clinicaltrials.gov\/study\/NCT05734508 (2024)(accessed 28 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib39","unstructured":"Fundaci\u00f3n39. Fundaci\u00f3n FLS de Lucha Contra el Sida las EI y la P de la S y la C, Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax): An Observational Prospective Cohort Study (accessed 28 November 2024)2024, https:\/\/clinicaltrials.gov\/study\/NCT05562323."},{"key":"10.1016\/j.colsurfb.2025.114829_bib40","unstructured":"BioNTech SE, A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines, https:\/\/clinicaltrials.gov\/study\/NCT05988203 (2024)(accessed 27 November 2024).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib41","unstructured":"National Institute of Allergy and Infectious Diseases, A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox, https:\/\/clinicaltrials.gov\/study\/NCT05740982 (2025) (accessed 3 February 2025).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib42","unstructured":"2024, Centers for Disease Control and Prevention, JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo (accessed 3 February 2025)https:\/\/clinicaltrials.gov\/study\/NCT02977715."},{"key":"10.1016\/j.colsurfb.2025.114829_bib43","unstructured":"2025, NYU Langone Health, New York City Observational Study of Mpox Immunity (NYC OSMI) Accessed 3 February 2025https:\/\/clinicaltrials.gov\/study\/NCT05654883."},{"key":"10.1016\/j.colsurfb.2025.114829_bib44","unstructured":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\", Study on Immunogenicity, Reactogenicity and Safety of the VAC\u22066 Vaccine in Volunteers Aged 18\u201360 Years, https:\/\/clinicaltrials.gov\/study\/NCT05846243 (2023)(accessed 3 February 2025).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib45","unstructured":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\", Safety and Tolerability Study of the VAC\u22066 Vaccine in Volunteers Aged 18\u201340 Years, https:\/\/clinicaltrials.gov\/study\/NCT05762523 (2023)(accessed 3 February 2025).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Morris","year":"1956","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.colsurfb.2025.114829_bib47","first-page":"281","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization","volume":"66","author":"Chanock","year":"1957","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.colsurfb.2025.114829_bib48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.colsurfb.2025.114829_bib49","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1099\/0022-1317-66-10-2111","article-title":"Two distinct subtypes of human respiratory syncytial virus","volume":"66","author":"Mufson","year":"1985","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib50","doi-asserted-by":"crossref","first-page":"e0283873","DOI":"10.1371\/journal.pone.0283873","article-title":"Molecular characterization of human respiratory syncytial virus in Seoul, South Korea, during 10 consecutive years, 2010\u20132019","volume":"18","author":"Kim","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.colsurfb.2025.114829_bib51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/infdis\/163.3.464","article-title":"Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B","volume":"163","author":"Waris","year":"1991","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.colsurfb.2025.114829_bib52","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/v16071100","article-title":"The epidemiology of respiratory syncytial virus: new trends and future perspectives","volume":"16","author":"Raffaldi","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.colsurfb.2025.114829_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3947\/ic.2024.0011","article-title":"Epidemiology and disease burden of respiratory syncytial virus infection in adults","volume":"56","author":"Kim","year":"2024","journal-title":"Infect. Chemother."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.114829_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2689-1050.1056","article-title":"Respiratory Syncytial Virus: Transmission and Treatment","volume":"5","author":"Jacob","year":"2023","journal-title":"Chem. Pharm. Res"},{"key":"10.1016\/j.colsurfb.2025.114829_bib55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/v10080446","article-title":"The morphology and assembly of respiratory syncytial virus revealed by cryo-electron tomography","volume":"10","author":"Ke","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib56","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.3390\/v14112396","article-title":"RSV replication, transmission, and disease are influenced by the RSV G protein","volume":"14","author":"Bergeron","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib57","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.36342","article-title":"Respiratory syncytial virus: A comprehensive review of transmission, pathophysiology, and manifestation","author":"Kaler","year":"2023","journal-title":"Cureus 15, e36342"},{"key":"10.1016\/j.colsurfb.2025.114829_bib58","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1414224","article-title":"Exploring monkeypox virus proteins and rapid detection techniques","volume":"14","author":"Sagdat","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib60","doi-asserted-by":"crossref","first-page":"e0210749","DOI":"10.1371\/journal.pone.0210749","article-title":"Structure basis of neutralization by a novel site II\/IV antibody against respiratory syncytial virus fusion protein","volume":"14","author":"Xie","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.colsurfb.2025.114829_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coi.2019.03.005","article-title":"Immunological goals for respiratory syncytial virus vaccine development","volume":"59","author":"Graham","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib62","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1099\/0022-1317-79-9-2221","article-title":"Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community","volume":"79","author":"Peret","year":"1998","journal-title":"J. Gen. Virol."},{"issue":"7","key":"10.1016\/j.colsurfb.2025.114829_bib63","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/v13071214","article-title":"Functional Features of the Respiratory Syncytial Virus G Protein","volume":"13","author":"Anderson","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105318","article-title":"The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis","volume":"107","author":"Anderson","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.colsurfb.2025.114829_bib65","doi-asserted-by":"crossref","first-page":"e1003309","DOI":"10.1371\/journal.ppat.1003309","article-title":"Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein","volume":"9","author":"Krzyzaniak","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.colsurfb.2025.114829_bib66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/mmi.15133","article-title":"Respiratory syncytial virus entry mechanism in host cells: A general overview","volume":"120","author":"Cadena-Cruz","year":"2023","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib67","doi-asserted-by":"crossref","first-page":"e0246770","DOI":"10.1371\/journal.pone.0246770","article-title":"Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats","volume":"16","author":"Martinez","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.colsurfb.2025.114829_bib68","doi-asserted-by":"crossref","first-page":"10508","DOI":"10.1128\/JVI.74.22.10508-10513.2000","article-title":"Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection","volume":"74","author":"Hallak","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib69","doi-asserted-by":"crossref","first-page":"e1009469","DOI":"10.1371\/journal.ppat.1009469","article-title":"The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines","volume":"17","author":"King","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.colsurfb.2025.114829_bib70","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1099\/vir.0.81786-0","article-title":"Unravelling the complexities of respiratory syncytial virus RNA synthesis","volume":"87","author":"Cowton","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib71","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1128\/JVI.74.13.6006-6014.2000","article-title":"Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus","volume":"74","author":"Fearns","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib72","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020587118","article-title":"Structural basis for IFN antagonism by human respiratory syncytial virus nonstructural protein 2","volume":"118","author":"Pei","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.colsurfb.2025.114829_bib73","article-title":"Systematic literature review of the signs and symptoms of respiratory syncytial virus","volume":"17","author":"Colosia","year":"2023","journal-title":"Influenza Other Respir. Virus"},{"key":"10.1016\/j.colsurfb.2025.114829_bib74","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s12519-023-00743-5","article-title":"Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis","volume":"19","author":"Jiang","year":"2023","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.colsurfb.2025.114829_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2500\/aap.2023.44.220094","article-title":"R.A. Settipane, Allergy and immunology: At the crossroad of inflammation and disease","volume":"44","author":"Bellanti","year":"2023","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.colsurfb.2025.114829_bib76","first-page":"1218","article-title":"Vaccines for respiratory syncytial virus prevention in older adults","volume":"58","author":"Wroblewski","year":"2024","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.colsurfb.2025.114829_bib77","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.colsurfb.2025.114829_bib78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02180-16","article-title":"Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus F primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (Alum) adjuvant","volume":"91","author":"Schneider-Ohrum","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib80","first-page":"83","article-title":"respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib81","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.colsurfb.2025.114829_bib82","doi-asserted-by":"crossref","first-page":"e1006837","DOI":"10.1371\/journal.ppat.1006837","article-title":"Human antibody recognition of antigenic site IV on pneumovirus fusion proteins","volume":"14","author":"Mousa","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.colsurfb.2025.114829_bib83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.hlife.2023.09.003","article-title":"A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein","volume":"1","author":"Dai","year":"2023","journal-title":"HLife"},{"key":"10.1016\/j.colsurfb.2025.114829_bib84","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2025.114829_bib85","doi-asserted-by":"crossref","first-page":"e1644","DOI":"10.1016\/S2214-109X(21)00455-1","article-title":"Respiratory syncytial virus: promising progress against a leading cause of pneumonia","volume":"9","author":"Ginsburg","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.colsurfb.2025.114829_bib86","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2025.114829_bib87","unstructured":"Merck, Merck announces FDA acceptance of Biologics License Application for Clesrovimab, https:\/\/www.merck.com\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-clesrovimab-an-investigational-long-acting-monoclonal-antibody-designed-to-protect-infants-from-rsv-disease-during-their-first-rsv\/ (2024)(accessed 3 February 2025).."},{"key":"10.1016\/j.colsurfb.2025.114829_bib88","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1016\/j.vaccine.2018.09.056","article-title":"Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset","volume":"36","author":"Mas","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.colsurfb.2025.114829_bib89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3201\/eid1801.110515","article-title":"Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006\u20132010","volume":"18","author":"Papenburg","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.colsurfb.2025.114829_bib90","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/nano.202300038","article-title":"Nanomaterials: An overview of synthesis, classification, characterization, and applications","volume":"4","author":"Mekuye","year":"2023","journal-title":"Nano Sel."},{"key":"10.1016\/j.colsurfb.2025.114829_bib91","doi-asserted-by":"crossref","first-page":"8948","DOI":"10.3390\/app14198948","article-title":"Nanostructured drug delivery systems in immunotherapy: An updated overview of nanotechnology-based therapeutic innovations","volume":"14","author":"Croitoru","year":"2024","journal-title":"Appl. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jconrel.2021.01.017","article-title":"Development of nanoparticle-delivery systems for antiviral agents: A review","volume":"331","author":"Delshadi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.114829_bib93","doi-asserted-by":"crossref","first-page":"13862","DOI":"10.3390\/ijms232213862","article-title":"Nanoparticles for antimicrobial agents delivery\u2014An up-to-date review","volume":"23","author":"Mercan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib94","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1007\/s11837-023-05897-1","article-title":"A comprehensive study on extracellular green synthesis, antibacterial activity and process design of metallic nanoparticles from Botryococcus braunii microalga","volume":"75","author":"Ko\u00e7er","year":"2023","journal-title":"JOM"},{"key":"10.1016\/j.colsurfb.2025.114829_bib95","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/2211738507666191024162042","article-title":"Nanoparticles and vaccine development","volume":"8","author":"Kheirollahpour","year":"2020","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1456060","article-title":"Advancements in monkeypox vaccines development: a critical review of emerging technologies","volume":"15","author":"Garcia-Atutxa","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2023.102636","article-title":"Addressing the resurgence of global monkeypox (Mpox) through advanced drug delivery platforms","volume":"56","author":"Mohanto","year":"2023","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.colsurfb.2025.114829_bib98","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12951-022-01477-8","article-title":"Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists","volume":"20","author":"Joudeh","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib99","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s13346-021-00945-2","article-title":"Advances in vaccine delivery systems against viral infectious diseases","volume":"11","author":"Kim","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.colsurfb.2025.114829_bib100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/nano11010137","article-title":"Inorganic and polymeric nanoparticles for human viral and bacterial infections prevention and treatment","volume":"11","author":"Aguilera-Correa","year":"2021","journal-title":"Nanomater. (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib101","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/jphp.12737","article-title":"Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles","volume":"69","author":"Javan","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib102","first-page":"108","article-title":"Design and evaluation of acyclovir-loaded solid lipid nanoparticles for sustained release","volume":"14","author":"Parthiban","year":"2020","journal-title":"Drug Invent. Today"},{"key":"10.1016\/j.colsurfb.2025.114829_bib103","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jmii.2023.02.010","article-title":"Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection","volume":"56","author":"Supramaniam","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.colsurfb.2025.114829_bib104","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3390\/pharmaceutics15041127","article-title":"Lipid nanoparticles as promising carriers for mRNA vaccines for viral lung infections","volume":"15","author":"Hajiaghapour Asr","year":"2023","journal-title":"Pharmaceutics"},{"issue":"42","key":"10.1016\/j.colsurfb.2025.114829_bib105","article-title":"Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity","volume":"8","author":"Patra","year":"2023","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.colsurfb.2025.114829_bib106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/acsinfecdis.8b00191","article-title":"ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection","volume":"5","author":"Thi","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.colsurfb.2025.114829_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/pharmaceutics13020206","article-title":"Lipid nanoparticles as delivery systems for RNA-based vaccines","volume":"13","author":"Aldosari","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.114829_bib108","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.3390\/ma14226812","article-title":"Polymer-based nanosystems\u2014A versatile delivery approach","volume":"14","author":"Niculescu","year":"2021","journal-title":"Materials"},{"key":"10.1016\/j.colsurfb.2025.114829_bib109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+\u2009T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2025.114829_bib110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cobme.2018.09.005","article-title":"J.J. Green, Polymeric nucleic acid delivery for immunoengineering","volume":"7","author":"Tzeng","year":"2018","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.colsurfb.2025.114829_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.120008","article-title":"Spectroscopic study of self-assembly of anti-hepatitis C virus sofosbuvir drug with bio-polymeric nanoparticles for improving the drug release effect","volume":"261","author":"Shawky","year":"2021","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.colsurfb.2025.114829_bib112","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/pharmaceutics13050672","article-title":"Polymer particles bearing recombinant LEL CD81 as trapping systems for hepatitis C virus","volume":"13","author":"Polyakov","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.114829_bib113","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2174\/1567201815666180604110457","article-title":"Hepatitis B antigen loaded biodegradable polymeric nanoparticles: formulation optimization and in-vivo immunization in BALB\/c mice","volume":"15","author":"Dewangan","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2025.114829_bib114","first-page":"216","article-title":"Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization","volume":"14","author":"Mosafer","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib115","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.ijbiomac.2017.09.078","article-title":"Encapsulation of zidovudine in PF-68 coated alginate conjugate nanoparticles for anti-HIV drug delivery","volume":"107A","author":"Joshy","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib116","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.msec.2018.08.015","article-title":"Novel core-shell dextran hybrid nanosystem for anti-viral drug delivery","volume":"93","author":"Joshy","year":"2018","journal-title":"Mater. Sci. Eng. C."},{"key":"10.1016\/j.colsurfb.2025.114829_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119676","article-title":"Acyclovir-loaded sulfobutyl ether-\u03b2-cyclodextrin decorated chitosan nanodroplets for the local treatment of HSV-2 infections","volume":"587","author":"Donalisio","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.114829_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114121","article-title":"Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition","volume":"231","author":"Sanna","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib119","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.3390\/ijms22094595","article-title":"Inorganic nanoparticles and composite films for antimicrobial therapies","volume":"22","author":"Spirescu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib120","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/v11121111","article-title":"Virucidal activity of gold nanoparticles synthesized by green chemistry using garlic extract","volume":"11","author":"Mel\u00e9ndez-Villanueva","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib121","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.3390\/ijms23147552","article-title":"Non-functionalized gold nanoparticles inhibit human papillomavirus (HPV) infection","volume":"23","author":"Valencia-Res\u00e9ndiz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib122","doi-asserted-by":"crossref","first-page":"484","DOI":"10.33263\/BRIAC135.484","article-title":"The optimization of curcumin-capped gold nanoparticle synthesis for FLuc-mRNA delivery to cervical cancer cells in vitro","volume":"13","author":"Venkatas","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2021.110576","article-title":"Dual engineered gold nanoparticle based synergistic prophylaxis delivery system for HIV\/AIDS","volume":"150","author":"Rawat","year":"2021","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib124","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00032719.2024.2313708","article-title":"Detection of Zika virus by the development of a colloidal gold nanoparticle-based immunosensor","volume":"58","author":"Cuapa-Gonz\u00e1lez","year":"2024","journal-title":"Anal. Lett."},{"key":"10.1016\/j.colsurfb.2025.114829_bib125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12951-020-00611-8","article-title":"Porous gold nanoparticles for attenuating infectivity of influenza A virus","volume":"18","author":"Kim","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib126","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/pharmaceutics16101288","article-title":"Development of targeted drug delivery system for the treatment of SARS-CoV-2 using aptamer-conjugated gold nanoparticles","volume":"16","author":"Park","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2025.114829_bib127","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s13346-022-01166-x","article-title":"Preclinical efficacy and safety of novel SNAT against SARS-CoV-2 using a hamster model","volume":"12","author":"Pokhrel","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.colsurfb.2025.114829_bib128","doi-asserted-by":"crossref","first-page":"24385","DOI":"10.1021\/acsami.6b06613","article-title":"Silver nanoparticle-based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways","volume":"8","author":"Li","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.colsurfb.2025.114829_bib129","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/v11080732","article-title":"Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection","volume":"11","author":"Morris","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.colsurfb.2025.114829_bib130","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/nano10112318","article-title":"An updated review on silver nanoparticles in biomedicine","volume":"10","author":"Gherasim","year":"2020","journal-title":"Nanomater. (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib131","article-title":"Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster\/silica composite sputtered coating","volume":"1","author":"Balagna","year":"2020","journal-title":"Open Ceram."},{"key":"10.1016\/j.colsurfb.2025.114829_bib132","first-page":"179","article-title":"Single-step biofabrication of silver nanocrystals using Naregamia alata: a cost effective and eco-friendly control tool in the fight against malaria, Zika virus and St. Louis encephalitis mosquito vectors","volume":"28","author":"Azarudeen","year":"2017","journal-title":"Sci"},{"key":"10.1016\/j.colsurfb.2025.114829_bib133","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00253-018-9488-1","article-title":"Green synthesis of silver nanoparticles from medicinal plants and evaluation of their antiviral potential against chikungunya virus","volume":"103","author":"Sharma","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib134","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/microorganisms11030629","article-title":"Silver nanoparticles: review of antiviral properties, mechanism of action and applications","volume":"11","author":"Luceri","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.colsurfb.2025.114829_bib135","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ijbiomac.2021.04.071","article-title":"Preparation of cellulose-based wipes treated with antimicrobial and antiviral silver nanoparticles as novel effective high-performance coronavirus fighter","volume":"181","author":"Hamouda","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib136","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.2147\/IJN.S214171","article-title":"Antiviral potential of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea","volume":"14","author":"Haggag","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2025.114829_bib137","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.2147\/IJN.S233766","article-title":"Hepatitis C virus NS3 protease and helicase inhibitors from Red Sea sponge (Amphimedon) species in green synthesized silver nanoparticles assisted by in silico modeling and metabolic profiling","volume":"15","author":"Shady","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2025.114829_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109382","article-title":"Monkeypox infection: the past, present, and future","volume":"113","author":"Upadhayay","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.33263\/BRIAC141.009","article-title":"Synthesis of graphene quantum dot zinc oxide nanocomposites: assessment of their antioxidant and antimicrobial activity","volume":"14","author":"Kahraman","year":"2024","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib140","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.3390\/ijms24098425","article-title":"Antiviral activity of zinc oxide nanoparticles against SARS-CoV-2","volume":"24","author":"Wolfgruber","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.881595","article-title":"Antiviral activity of zinc oxide nanoparticles and tetrapods against the hepatitis E and hepatitis C viruses","volume":"13","author":"Gupta","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib142","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/molecules28010266","article-title":"Green synthesized zinc oxide nanoparticles based on Cestrum diurnum L. of potential antiviral activity against human corona 229-E virus","volume":"28","author":"Alrabayah","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.colsurfb.2025.114829_bib143","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.2147\/IJN.S339404","article-title":"Antiviral activity of zinc oxide nanoparticles mediated by Plumbago indica L. extract against herpes simplex virus type 1 (HSV-1)","volume":"16","author":"Melk","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2025.114829_bib144","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/ijms24021629","article-title":"Antimicrobial clothing based on electrospun fibers with ZnO nanoparticles","volume":"24","author":"Preda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12929-019-0563-4","article-title":"Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine","volume":"26","author":"Ghaffari","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib146","first-page":"317","article-title":"Comparative analysis of novel iron oxide nanoparticles synthesized by different approaches with evaluation of their antibacterial activities","volume":"13","author":"Abdussalam-Mohammed","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymeth.2021.04.018","article-title":"Magnetite nanoparticles: synthesis methods \u2013 a comparative review","volume":"199","author":"Niculescu","year":"2022","journal-title":"Methods"},{"key":"10.1016\/j.colsurfb.2025.114829_bib148","doi-asserted-by":"crossref","first-page":"582","DOI":"10.33263\/BRIAC136.582","article-title":"Assessment of the functionalization of chitosan\/iron oxide nanoparticles","volume":"13","author":"Ismail","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105465","article-title":"A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection","volume":"153","author":"Abo-Zeid","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib150","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jiac.2018.12.006","article-title":"Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus","volume":"25","author":"Kumar","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.colsurfb.2025.114829_bib151","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12032-022-01780-2","article-title":"Folate functionalized gold-coated magnetic nanoparticles effect in combined electroporation and radiation treatment of HPV-positive oropharyngeal cancer","volume":"39","author":"Ahmadi Kamalabadi","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib152","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.procbio.2023.04.011","article-title":"Iron oxide-silver-curcumin nanocomposite acts against HPV16 positive cervical cancer cell siha by triggering crosstalk between autophagy and apoptosis primarily via breach in cellular redox equilibrium","volume":"130","author":"Nath","year":"2023","journal-title":"Process Biochem"},{"key":"10.1016\/j.colsurfb.2025.114829_bib153","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.xphs.2021.10.018","article-title":"Development of a T cell-targeted siRNA delivery system against HIV-1 using modified superparamagnetic iron oxide nanoparticles: an in vitro study","volume":"111","author":"Kamalzare","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111227","article-title":"Non-nuke HIV-1 inhibitor shuttled by mesoporous silica nanoparticles effectively slows down HIV-1 replication in infected human cells","volume":"194","author":"Fotooh Abadi","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2025.114829_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105488","article-title":"Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses","volume":"210","author":"Tng","year":"2023","journal-title":"Antivir. Res"},{"key":"10.1016\/j.colsurfb.2025.114829_bib156","first-page":"39","article-title":"Antiviral adsorption activity of porous silicon nanoparticles against different pathogenic human viruses","volume":"7","author":"Osminkina","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.colsurfb.2025.114829_bib157","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1021\/acsabm.0c00814","article-title":"Galactose functionalized mesoporous silica nanoparticles as delivery vehicle in the treatment of hepatitis C infection","volume":"3","author":"Mukherjee","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.colsurfb.2025.114829_bib158","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpb.2023.09.015","article-title":"Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice","volume":"192","author":"Barbey","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.114829_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.micromeso.2021.110886","article-title":"Curcumin-loaded mesoporous silica nanoparticles with dual-imaging and temperature control inhibits the infection of Zika virus","volume":"314","author":"Lo","year":"2021","journal-title":"Microporous Mesoporous Mater."},{"key":"10.1016\/j.colsurfb.2025.114829_bib160","article-title":"Mini-review for an electrocatalytic application of carbon nanotube in medical fields \u2013 tissue engineering, drug delivery, cancer and SARS-CoV-2","volume":"13","author":"Law","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib161","first-page":"258","article-title":"Molecular simulations of 6-gingerol loading on graphene and graphene oxide for drug delivery applications","volume":"13","author":"Al-Akhras","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4067\/S0717-97072023000105781","article-title":"Treating Omicron Ba.4 & Ba.5 via herbal antioxidant Asafoetida: a DFT study of carbon nanocarrier in drug delivery","volume":"68","author":"Mollaamin","year":"2023","journal-title":"J. Chil. Chem. Soc."},{"key":"10.1016\/j.colsurfb.2025.114829_bib163","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00705-024-06117-0","article-title":"Graphene oxide nanoparticles inhibit H9N2 influenza A virus infectivity by destroying viral coat proteins","volume":"169","author":"Wang","year":"2024","journal-title":"Arch. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib164","article-title":"Antiviral properties of porous graphene, graphene oxide and graphene foam ultrafine fibers against Phi6 bacteriophage","volume":"9","author":"Gungordu Er","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib165","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1039\/C7NR06520E","article-title":"Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection","volume":"9","author":"Yang","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.colsurfb.2025.114829_bib166","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/acsbiomaterials.1c01184","article-title":"Graphene-based nanomaterials in fighting the most challenging viruses and immunogenic disorders","volume":"8","author":"Ebrahimi","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.colsurfb.2025.114829_bib167","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1021\/acsami.6b01681","article-title":"High efficiency of functional carbon nanodots as entry inhibitors of herpes simplex virus type 1","volume":"8","author":"Barras","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.colsurfb.2025.114829_bib168","first-page":"249","article-title":"Investigations on TGA-capped CdTe quantum-dots for detection and quantitative assessment of chikungunya infection through lateral flow immunoassay","volume":"13","author":"Chauhan","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101957","article-title":"Development of antiviral carbon quantum dots that target the Japanese encephalitis virus envelope protein","volume":"298","author":"Chen","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.colsurfb.2025.114829_bib170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2022.09.019","article-title":"Folic acid-functionalized graphene quantum dots: synthesis, characterization, radiolabeling with radium-223 and antiviral effect against Zika virus infection","volume":"180","author":"Pijeira","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.114829_bib171","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/jctb.7036","article-title":"Quantum dots against SARS-CoV-2: diagnostic and therapeutic potentials","volume":"97","author":"Rabiee","year":"2022","journal-title":"J. Chem. Technol. Biotechnol."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.114829_bib172","doi-asserted-by":"crossref","first-page":"411","DOI":"10.34172\/apb.2023.065","article-title":"Biosynthesis of quantum dots and their therapeutic applications in the diagnosis and treatment of cancer and SARS-CoV","volume":"13","author":"Zorab","year":"2023","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.colsurfb.2025.114829_bib173","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2021.08.011","article-title":"Nanomedicine based approaches for combating viral infections","volume":"338","author":"Shah","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.114829_bib174","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/vaccines9060558","article-title":"Recent advances and future perspectives in polymer-based nanovaccines","volume":"9","author":"Pippa","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106156","article-title":"Progress and prospects on vaccine development against monkeypox infection","volume":"180","author":"Saadh","year":"2023","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.colsurfb.2025.114829_bib176","article-title":"Advancing Aggregation-Induced Emission-Derived Biomaterials in Viral, Tuberculosis, and Fungal Infectious Diseases","volume":"6","author":"Wang","year":"2025","journal-title":"Aggregate"},{"key":"10.1016\/j.colsurfb.2025.114829_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105799","article-title":"Monkeypox: emerging virus of concern; antivirals and vaccines therapeutic options","volume":"173","author":"Obeid","year":"2022","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.colsurfb.2025.114829_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.867119","article-title":"Biological nanoparticles in vaccine development","volume":"10","author":"Curley","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib179","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5114\/bta.2022.120709","article-title":"Licensed liposomal vaccines and adjuvants in the antigen delivery system","volume":"103","author":"Krasnopolsky","year":"2022","journal-title":"Biotechnol. (Pozn. )"},{"key":"10.1016\/j.colsurfb.2025.114829_bib180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1208\/s12248-021-00676-9","article-title":"Nano\/microparticle formulations for universal influenza vaccines","volume":"24","author":"Hendy","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.colsurfb.2025.114829_bib181","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.vaccine.2009.05.029","article-title":"Eleven years of Inflexal V\u2014a virosomal adjuvanted influenza vaccine","volume":"27","author":"Herzog","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.colsurfb.2025.114829_bib182","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/vaccines11081391","article-title":"Advances in adjuvanted influenza vaccines","volume":"11","author":"Shichinohe","year":"2023","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib183","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.vaccine.2023.05.011","article-title":"Advances in intranasal vaccine delivery: a promising non-invasive route of immunization","volume":"41","author":"Kehagia","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.colsurfb.2025.114829_bib184","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.vaccine.2011.01.009","article-title":"A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity","volume":"29","author":"Even-Or","year":"2011","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.colsurfb.2025.114829_bib185","article-title":"Differences in HPV-specific antibody Fc-effector functions following Gardasil\u00ae and Cervarix\u00ae vaccination","volume":"8","author":"Roy","year":"2023","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.colsurfb.2025.114829_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.109270","article-title":"An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus","volume":"35","author":"Tian","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.colsurfb.2025.114829_bib187","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3540","article-title":"An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge","volume":"15","author":"Freyn","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.colsurfb.2025.114829_bib188","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202401372","article-title":"Development of gold nanoparticle based colorimetric monkeypox biosensors suitable for point of care (POC) analysis","volume":"9","author":"Perk","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.colsurfb.2025.114829_bib189","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28479","article-title":"Rapid detection of monkeypox virus by multiple cross displacement amplification combined with nanoparticle-based biosensor platform","volume":"95","author":"Zhou","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib190","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.matt.2024.01.004","article-title":"Macrophage-derived biomimetic nanoparticles for light-driven theranostics toward Mpox","volume":"7","author":"Wang","year":"2024","journal-title":"Matter"},{"key":"10.1016\/j.colsurfb.2025.114829_bib191","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.vaccine.2024.02.027","article-title":"Rapid and highly potent humoral responses to mpox nanovaccine candidates adjuvanted by thermostable scaffolds","volume":"42","author":"Yan","year":"2024","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.colsurfb.2025.114829_bib192","article-title":"Antibiotic-loaded lactoferrin nanoparticles as a platform for enhanced infection therapy through targeted elimination of intracellular bacteria","volume":"19","author":"Wang","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib193","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-12-817778-5.00007-5","article-title":"Chapter 7 \u2013 Nanoparticle-based vaccines: opportunities and limitations","author":"Diaz-Ar\u00e9valo","year":"2020","journal-title":"Nanopharmaceuticals"},{"key":"10.1016\/j.colsurfb.2025.114829_bib194","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jconrel.2022.12.022","article-title":"Protein-based nanocages for vaccine development","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2025.114829_bib195","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.03.002","article-title":"Bioengineered protein-based nanocage for drug delivery","volume":"106","author":"Lee","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2025.114829_bib196","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3389\/fimmu.2018.01432","article-title":"New routes and opportunities for modular construction of particulate vaccines: stick, click, and glue","volume":"9","author":"Brune","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib197","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.chembiol.2021.07.005","article-title":"DogCatcher allows loop-friendly protein\u2013protein ligation","volume":"29","author":"Keeble","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib198","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1039\/D2SC02772K","article-title":"High order assembly of multiple protein cages with homogeneous sizes and shapes via limited cage surface engineering","volume":"14","author":"Oh","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.colsurfb.2025.114829_bib199","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-12-802302-0.00003-0","article-title":"Chapter 4 \u2013 Virus-like particle and nanoparticle vaccines","author":"Kanekiyo","year":"2017","journal-title":": Hum. Vaccin."},{"key":"10.1016\/j.colsurfb.2025.114829_bib200","first-page":"367","article-title":"Novel protein therapeutics created using the elastin-like polypeptide platform","volume":"36","author":"Bidwell","year":"2021","journal-title":"Physiol. (Bethesda)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib201","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12951-023-02184-8","article-title":"The construction of elastin-like polypeptides and their applications in drug delivery system and tissue repair","volume":"21","author":"Guo","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2025.114829_bib202","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/vaccines12030294","article-title":"Design and preclinical evaluation of a nanoparticle vaccine against respiratory syncytial virus based on the attachment protein G","volume":"12","author":"Voorzaat","year":"2024","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib203","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3390\/vaccines12121354","article-title":"RSV vaccine with nanoparticle-based poly-sorbitol transporter (PST) adjuvant improves respiratory protection against RSV through inducing both systemic and mucosal humoral immunity","volume":"12","author":"Jung","year":"2024","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib204","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba6466","article-title":"A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain","volume":"5","author":"Swanson","year":"2020","journal-title":"Sci. Immunol."},{"issue":"16","key":"10.1016\/j.colsurfb.2025.114829_bib205","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccin."},{"issue":"85","key":"10.1016\/j.colsurfb.2025.114829_bib206","article-title":"An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus","volume":"6","author":"Zuniga","year":"2021","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.colsurfb.2025.114829_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115597","article-title":"Nanovaccines: a game changing approach in the fight against infectious diseases","volume":"167","author":"Priyanka","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.colsurfb.2025.114829_bib208","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/v14071553","article-title":"Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2","volume":"14","author":"Mohamed","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.colsurfb.2025.114829_bib209","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/vaccines13020126","article-title":"Revolutionizing Nanovaccines: A New Era of Immunization","volume":"13","author":"Saleh","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.colsurfb.2025.114829_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.colsurfb.2025.114829_bib211","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3390\/vaccines10111946","article-title":"Nanoparticle-Based Delivery Systems for Vaccines","volume":"10","author":"Bezbaruah","year":"2022","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.colsurfb.2025.114829_bib212","series-title":"Pharmaceutical Process Engineering and Scale-up Principles. AAPS Introductions in the Pharmaceutical Sciences","article-title":"Manufacturing process of nanoparticles","author":"Chauhan","year":"2023"}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776525003364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776525003364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:05:39Z","timestamp":1778515539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776525003364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":212,"alternative-id":["S0927776525003364"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2025.114829","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology-driven enhancement and modulation of immune responses in monkeypox and respiratory syncytial virus nanovaccine research","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2025.114829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114829"}}